查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095336

急性骨髓性白血病治療市場－2026-2032年全球市場預測

Acute Myeloid Leukemia Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，急性骨髓性白血病治療市場規模將成長至 76.2 億美元，複合年成長率為 10.41%。

主要市場統計數據
基準年 2025 38.1億美元
預計年份：2026年 41.9億美元
預測年份 2032 76.2億美元
複合年成長率 (%) 10.41%

細胞毒性化學療法在臨床實踐中正迅速發展，從廣泛應用的急性骨髓性白血病化療轉向精準腫瘤學、突變標靶治療、抗體療法、最佳化的造血幹細胞移植策略以及改進的支持治療。 AMYL急性骨髓性白血病骨髓惡性腫瘤，其特徵是未成熟髓系細胞的克隆性增殖。治療選擇越來越依賴患者的健身、細胞遺傳學風險、可測量的殘留病灶狀態以及分子突變，例如 FLT3、IDH1、IDH2、NPM1、TP53 和其他疾病相關的異常。現有的血液學指南強調，診斷時的基因組和細胞遺傳學評估是風險分層和治療選擇的核心，復發時的複檢有助於識別克隆演變和新出現的可靶向突變。主要醫療保健計劃的監管批准正在擴大新診斷、復發、難治性、老年和仿單標示外患者的治療選擇，同時更新的臨床指南繼續強調在診斷和復發時進行全面的基因組檢測。目前的治療方案包括強化誘導和強化化療、基於低甲基化劑的聯合治療、標靶抑制劑、BCL-2抑制策略、CD33標靶療法、維持治療、急性骨髓性白血病造血幹細胞移植以及臨床實驗免疫療法。人口老化、診斷可及性的提高、次世代定序的廣泛應用以及在真實臨床實踐中平衡緩解深度與毒性、生活品質和治療可行性的需求，進一步推動了對急性髓系白血病有效治療的需求。

急性骨髓性白血病治療格局的變革性變化

隨著分子層級分層在治療方案製定中扮演核心角色，急性骨髓性白血病)的治療格局正在改變。傳統上，許多患者接受類似的化療，而現代治療越來越依賴基因組和細胞遺傳學風險分層來確定誘導強度、標靶治療選擇、移植時機以及緩解後維持治療。 FLT3 抑制劑是 FLT3 突變型 AML 的關鍵治療手段，而 IDH 抑制劑則為 IDH1 和 IDH2 突變型 AML 提供了突變特異性治療選擇。此外，基於維奈托克的低強度方案徹底改變了老年患者和不適合接受強化化療患者的治療前景。維持治療的臨床意義日益凸顯，尤其是在緩解期患者（不適合立即進行移植）以及需要降低多學科治療後復發風險的患者。可測量的殘留病灶評估也正在改變臨床決策，有助於識別復發高風險患者，並確定移植和強化治療策略。同時，針對menin抑制劑、雙特異性抗體、細胞療法、巨噬細胞查核點調節以及旨在克服KMT2A重排和NPM1突變型急性髓系白血病（AML）抗藥性的聯合治療的研究正在不斷擴展。這些變化凸顯了生物標記檢測基礎設施、多學科診療路徑、不利事件管理、抗生素和輸血支持以及保險公司對獲得先進診斷和標靶治療的支持的重要性日益增加。

人工智慧在急性骨髓性白血病治療的累積影響

人工智慧正逐步影響急性骨髓性白血病(AML) 治療的各個階段，從藥物發現和診斷到臨床試驗設計和病患管理。在藥物發現方面，機器學習模型正被用於識別治療標靶、預測化合物活性、最佳化聯合治療策略以及分析遺傳複雜的 AML 亞型中的抗藥性機制。在臨床研究中，人工智慧驅動的患者配對整合了來自電子健康記錄的基因組譜、實驗室指標、先前治療史和合併症數據，以識別合格生物標記主導臨床試驗條件的受試者。在診斷方面，計算病理學和流式細胞技術分析提高了原始細胞表徵和疾病監測的一致性，而基因組解讀工具則幫助臨床醫生根據治療相關性對突變進行分類。此外，人工智慧驅動的風險建模研究也不斷推進，旨在提高預測復發、治療相關毒性、感染風險、移植結果以及可測量殘留病灶動態變化的準確性。然而，人工智慧的累積效應取決於檢驗的資料集、透明的演算法、資料互通性、監管監督、隱私保護以及與專家判斷相輔相成而非取而代之的臨床整合。在急性髓性白血病（AML）治療中，預計其最大的短期價值將來自於加速精準醫療工作流程、提高臨床試驗患者入組效率、早期發現高風險疾病模式以及建立更個人化的治療方案。

關於急性骨髓性白血病治療的關鍵區域見解

急性骨髓性白血病)治療的區域趨勢反映了診斷基礎設施、報銷系統、移植能力、臨床試驗參與機會以及血液病專家網路等方面的差異。在北美，已建立的基於指南的診療路徑和先進的支持治療促進了基因組檢測、突變標靶治療、多學科白血病計畫以及臨床試驗的積極應用。在歐洲，協調的血液疾病網路、國家癌症計畫、移植登記系統以及實證方案的廣泛應用都卓有成效，但治療機會和報銷標準因國家和醫療評估流程而異。亞太地區的特點是腫瘤基礎設施的快速擴張、次世代定序的廣泛應用以及骨髓惡性腫瘤研究參與度的提高，其中日本、中國、韓國、澳洲和印度在治療機會和臨床開發方面發揮著重要作用。在拉丁美洲，隨著癌症中心、大學附屬血液疾病計畫和公共衛生舉措的擴展，急性髓系白血病（AML）的診斷和治療可及性持續提高，但報銷和專科醫療體系的差異影響著患者獲得標靶治療和移植的機會。在中東，尤其是在擁有國家癌症戰略和醫療城網路的高所得醫療體系中，三級癌症診療服務、基因組醫學計畫和移植計畫正在加強。非洲面臨一些最嚴峻的可近性限制，包括分子診斷的局限性、缺乏專科血液疾病中心、輸血和感染控制資源的限制以及支持性治療方面的差異。然而，區域癌症計畫、病理學培訓和國際合作正在提高人們對AML的認知，改善診斷能力，並最佳化轉診途徑。

影響急性髓系白血病治療取得和部署的關鍵群體特定見解

集團層面的醫療保健和政策結構影響急性骨髓性白血病(AML) 治療的評估、資金籌措和實施。七國集團 (G7) 國家通常擁有成熟的監管體系、先進的腫瘤基礎設施和健全的臨床試驗生態系統，以及相對廣泛的基因組診斷、標靶治療、移植和支持性治療，使其成為指南實施和真實世界證據生成的重要標竿。歐盟 (EU) 支持監管評估的協調、跨境研究合作、罕見疾病和癌症研究網路以及系統性的衛生技術評估流程；然而，患者能否獲得治療仍取決於各國的醫保報銷政策。金磚國家 (BRICS) 由於其龐大的患者群體、不斷擴大的血液病診療能力、國內臨床研究活動以及對精準腫瘤學投入的增加，在 AML 治療中發揮著日益重要的作用；然而，都市區之間的醫療資源獲取差距依然存在。東南亞國協正在透過擴大三級醫療機構、引入社區轉診模式和提高檢測能力來改善癌症診療服務。然而，成本效益和專科醫生的可近性仍然影響著治療的可近性。海灣合作理事會（GCC）國家的醫療衛生系統在國家醫療衛生轉型計劃和集中式專科醫療模式的支持下，正加大對先進癌症中心、分子檢測、國際標準化治療路徑和移植能力的投資。北約成員國與北美和歐洲的高所得市場高度重合，這些地區的國防相關研究能力、生物醫學創新生態系統、緊急準備框架和協調一致的衛生安全計畫可以間接支持與複雜血液腫瘤治療相關的先進診斷技術、數據基礎設施和具有韌性的藥品供應鏈。

各國對急性骨髓性白血病治療的重點見解

各國之間的差異顯著影響急性骨髓性白血病)治療的可近性。在美國，分子檢測、AML標靶治療、大學附屬白血病中心以及基於生物標記的臨床試驗已廣泛普及，但保險方案的設計和成本效益比仍然是影響治療可近性的關鍵因素。在加拿大，省級醫療保健系統提供基於指南的 AML 治療，區域性資金籌措政策促進了移植技術和基因組檢測的高水準發展。墨西哥和巴西透過公立和私立癌症網路加強了血液腫瘤系統，但不同地區和保險公司提供的專科診斷、新型標靶治療和移植服務的機會各不相同。在英國，集中化的血液學專家團隊、國家治療方案和結構化的技術評估流程支持實證醫學的應用。同時，德國和法國擁有強大的白血病研究網路、移植基礎設施、分子診斷能力和專科血液中心。義大利和西班牙透過完善的血液疾病網路提供先進的急性髓性白血病（AML）治療，但區域健保體系和醫院資源會影響治療的及時性。俄羅斯擁有專業的血液疾病機構和移植項目，但地理位置、轉診途徑和藥物供應情況各不相同。中國正在大規模拓展AML研究、基因組檢測和醫院腫瘤治療，而印度儘管面臨成本挑戰，但仍在透過大型癌症中心改善治療可近性、擴大移植活動和廣泛更新診斷技術方面取得進展。日本擁有高度發達的血液疾病治療體系，臨床研究實力雄厚，老齡化患者需求旺盛，標靶治療的法規核准也取得了進展。澳洲透過覆蓋全國的專家網路和參與臨床試驗提供先進的AML管理，而韓國擁有先進的三級醫療設施、分子診斷、移植能力和積極的骨髓惡性腫瘤研究，為現代AML治療方案提供了支持。

為急性髓性白血病治療行業的領導者提供的實用建議

急性骨髓性白血病治療領域的產業領導者應優先考慮實證精準醫療策略，將療法研發、診斷可及性和實際臨床需求結合。首先，應將全面的生物標記檢測（包括診斷和復發時的快速分子譜分析）整合到患者照護階段，以支持選擇合適的治療方案。其次，研發項目應著重於合理的聯合治療，以解決抗藥性機制、提高緩解期的維持率，並控制老年患者和合併基礎疾病患者的毒性。第三，相關人員應投資於微小殘留疾病（MRD）的標準化，因為基於MRD的決策在復發風險評估、移植計畫和緩解後策略中正變得越來越重要。第四，臨床試驗設計應在科學合理的範圍內擴大入組標準，促進老年人和弱勢群體的入組，並採用分散式或混合式方法以減少參與障礙。第五，尤其是在分子檢測和移植能力參差不齊的地區，應根據臨床價值、診斷基礎設施狀況和醫療系統的財政能力來制定准入策略。最後，領導者應加強藥物安全監測、支持性護理方案、血液科團隊教育以及數據合作，以產生有關安全性、治療順序、生活品質、用藥依從性、耐受性和長期結果的真實世界數據。

用於分析治療急性骨髓性白血病藥物的調查方法

本執行摘要採用系統性的二手調查方法編寫，重點關注資訊來源的檢驗且有數據支持的證據。研究途徑包括審查血液疾病治療指南、法規核准文件、同行評審的腫瘤學日誌、臨床試驗註冊庫、癌症相關出版刊物、移植和血液學會資料以及公開的醫療保健系統資源。評估證據與急性骨髓性白血病治療的相關性，包括療法、分子生物標記、患者細分、區域可及性、臨床發展趨勢以及人工智慧 (AI) 等新興技術。資訊在多個可信賴資訊來源之間進行交叉檢驗，以減少偏差並確保與當前臨床發現的一致性。此調查方法強調對治療創新、醫療服務趨勢、診斷應用和政策因素進行定性分析，而不依賴市場規模估算、市場佔有率估算或預測。本分析整合了來自可觀察的醫療基礎設施、法律規範、癌症治療接受能力、臨床指南實施情況、移植接受率以及精準腫瘤學實踐應用等方面的區域、群體和國家層面的具體信息，旨在為參與急性髓系白血病（AML）藥物研發、診斷、臨床研究、准入規劃和醫療服務等相關利益相關相關人員提供策略決策支援。

結論：急性骨髓性白血病治療藥物的未來發展方向

急性骨髓性白血病)的治療正邁向更個人化的時代，其特點是分子診斷、標靶治療、聯合治療、可測量殘留病灶的評估以及免疫療法和細胞療法的臨床探索不斷擴展。治療模式正從標準化的化療轉向能夠反映疾病生物學特徵、患者身體狀況、復發風險和治療耐受性的適應性策略。人工智慧 (AI) 有望透過改善標靶發現、患者與臨床匹配、風險預測和診斷結果解讀來加速這一轉變。然而，這前提是相關工具已通過臨床檢驗並得到負責任的整合。區域和國家層級的醫療資源取得仍然存在差異，醫療體系較為發達的地區能夠更快地部署精準的 AML 治療方案，而資源匱乏的地區在診斷、移植、支持治療和經濟負擔方面仍然面臨諸多障礙。相關人員面臨的最大機會在於將創新與可操作的實施相結合。具體而言，這包括加快檢測速度、最佳化治療方案、進行全面的臨床試驗、利用可靠的真實世界數據以及建立永續的醫療服務獲取模式。由於急性髓系白血病（AML）仍然是一種進展迅速且臨床表現複雜的疾病，因此，在治療、診斷、數位基礎設施、臨床專業知識和以患者為中心的醫療服務等領域開展合作，對於未來的進展至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：急性骨髓性白血病治療市場：依治療類型分類

  • 化療
    • 誘導化療
    • 強化化療
  • 標靶治療
  • 免疫療法
  • 幹細胞移植療法
  • 表觀遺傳療法
  • 支持性護理

第8章：急性骨髓性白血病治療藥物市場：依疾病類型分類

  • De Novo AML
  • 續發性白血病
  • 難治性急性骨髓性白血病
  • 急性早幼粒細胞白血病（APL）
  • 蛋白酪氨酸激酶抑制劑

第9章：急性骨髓性白血病治療市場：依分子突變類型分類

  • FLT3變異型急性骨髓性白血病
  • IDH變異型急性骨髓性白血病
  • NPM1變異型急性骨髓性白血病
  • TP53變異型急性骨髓性白血病
  • RUNX1 變異型急性骨髓性白血病

第10章：急性骨髓性白血病治療市場：依藥物類別分類

  • 細胞毒性藥物
  • 低甲基化劑
  • 蛋白酪氨酸激酶抑制劑
  • BCL-2抑制劑
  • 單株抗體

第11章：急性骨髓性白血病治療市場：依給藥途徑分類

  • 口服
  • 腸外
  • 鞘內給藥

第12章：急性骨髓性白血病治療市場：依最終用戶分類

  • 醫院
  • 癌症專科診所
  • 門診手術中心
  • 研究機構
  • 居家照護環境

第13章：急性骨髓性白血病治療市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：急性骨髓性白血病治療藥物市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章：急性骨髓性白血病治療市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Actinium Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc. by Otsuka Group
  • Celgene Corporation
  • CTI BioPharma Corp.
  • Cyclacel Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • MEI Pharma, Inc.
  • Merck KGaA
  • Merus NV
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Partner Therapeutics, Inc.
  • Pfizer Inc.
  • Rigel Pharmaceuticals, Inc.
  • Sanofi SA
  • Servier Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol Myers Squibb Company
Product Code: MRR-02026C4C8B97

The Acute Myeloid Leukemia Therapeutics Market is projected to grow by USD 7.62 billion at a CAGR of 10.41% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.81 billion
Estimated Year [2026] USD 4.19 billion
Forecast Year [2032] USD 7.62 billion
CAGR (%) 10.41%

Acute myeloid leukemia therapeutics are evolving rapidly as clinical practice shifts from broadly applied cytotoxic chemotherapy toward precision oncology, mutation-directed regimens, antibody-based approaches, optimized stem cell transplantation strategies, and improved supportive care. Acute myeloid leukemia is a biologically heterogeneous hematologic malignancy characterized by clonal expansion of immature myeloid cells, and treatment selection increasingly depends on patient fitness, cytogenetic risk, measurable residual disease status, and molecular alterations such as FLT3, IDH1, IDH2, NPM1, TP53, and other disease-defining abnormalities. According to established hematology guidance, genomic and cytogenetic assessment at diagnosis is now central to risk classification and therapy selection, while repeat testing at relapse can identify clonal evolution and emerging targetable mutations. Regulatory approvals across major healthcare systems have expanded options for newly diagnosed, relapsed, refractory, older, and medically unfit patients, while updated clinical guidelines continue to emphasize comprehensive genomic testing at diagnosis and relapse. The therapeutic landscape now spans intensive induction and consolidation chemotherapy, hypomethylating agent-based combinations, targeted inhibitors, BCL-2 inhibition strategies, CD33-directed therapy, maintenance treatment, allogeneic hematopoietic stem cell transplantation, and investigational immunotherapies. Demand for effective acute myeloid leukemia treatment is further shaped by aging populations, improved diagnostic access, growing use of next-generation sequencing, and the need to balance remission depth with toxicity, quality of life, and treatment feasibility in real-world settings.

Transformative Shifts in the Acute Myeloid Leukemia Therapeutics Landscape

The acute myeloid leukemia therapeutics landscape is undergoing transformative change as molecular stratification becomes central to treatment planning. Historically, many patients received similar chemotherapy backbones, but contemporary care increasingly uses genomic and cytogenetic risk classification to guide induction intensity, targeted therapy selection, transplant timing, and post-remission maintenance. FLT3 inhibitors have become an important component for FLT3-mutated disease, IDH inhibitors provide mutation-specific options for IDH1- and IDH2-mutated AML, and venetoclax-based low-intensity regimens have changed treatment expectations for older adults and patients unsuitable for intensive chemotherapy. Maintenance therapy is gaining broader clinical relevance, particularly for patients in remission who are not immediate transplant candidates or who require relapse-risk mitigation after intensive therapy. Measurable residual disease assessment is also reshaping clinical decision-making by helping identify patients at elevated relapse risk and informing transplant or consolidation strategies. At the same time, research is expanding into menin inhibition for KMT2A-rearranged and NPM1-mutated AML, bispecific antibodies, cellular therapies, macrophage checkpoint modulation, and combinations designed to overcome resistance. These shifts are increasing the importance of biomarker testing infrastructure, multidisciplinary care pathways, adverse event management, antimicrobial and transfusion support, and payer-supported access to advanced diagnostics and targeted medicines.

Cumulative Impact of Artificial Intelligence on AML Therapeutics

Artificial intelligence is beginning to influence acute myeloid leukemia therapeutics across discovery, diagnosis, trial design, and patient management. In drug discovery, machine learning models are being applied to identify therapeutic targets, predict compound activity, optimize combination strategies, and analyze mechanisms of resistance in genetically complex AML subtypes. In clinical research, AI-enabled patient matching can help identify eligible participants for biomarker-driven trials by integrating genomic profiles, laboratory values, prior therapies, and comorbidity data from electronic health records. In diagnostics, computational pathology and flow cytometry analytics support more consistent blast characterization and disease monitoring, while genomic interpretation tools can assist clinicians in classifying mutations according to therapeutic relevance. AI-driven risk modeling is also being explored to improve prediction of relapse, treatment-related toxicity, infection risk, transplant outcomes, and measurable residual disease dynamics. However, the cumulative impact of artificial intelligence depends on validated datasets, transparent algorithms, data interoperability, regulatory oversight, privacy safeguards, and clinical integration that supports, not replaces, specialist judgment. For AML therapeutics, the highest near-term value lies in accelerating precision medicine workflows, improving clinical trial enrollment efficiency, detecting high-risk disease patterns earlier, and enabling more individualized treatment sequencing.

Key Regional Insights Across Acute Myeloid Leukemia Therapeutics

Regional dynamics in acute myeloid leukemia therapeutics reflect differences in diagnostic infrastructure, reimbursement systems, transplant capacity, clinical trial access, and hematology specialist networks. North America demonstrates strong adoption of genomic testing, mutation-directed treatment, multidisciplinary leukemia programs, and clinical trial participation, supported by established guideline-driven care pathways and access to advanced supportive care. Europe benefits from coordinated hematology networks, national cancer plans, transplant registries, and broad use of evidence-based protocols, though access timelines and reimbursement criteria vary by country and health technology assessment processes. Asia-Pacific is marked by rapid expansion of oncology infrastructure, growing adoption of next-generation sequencing, and increased participation in hematologic malignancy research, with Japan, China, South Korea, Australia, and India playing important roles in treatment access and clinical development. Latin America continues to improve AML diagnosis and therapy availability through expanding cancer centers, academic hematology programs, and public health initiatives, while variability in reimbursement and specialized care capacity affects access to targeted agents and transplantation. The Middle East is strengthening tertiary oncology services, genomic medicine initiatives, and transplant programs, particularly in higher-income health systems with national cancer strategies and medical city networks. Africa faces the greatest access constraints, including limited molecular diagnostics, fewer specialized hematology centers, constrained transfusion and infection-management resources, and gaps in supportive care, but regional cancer control efforts, pathology training, and international collaborations are improving awareness, diagnostic capacity, and treatment referral pathways.

Key Group Insights Shaping AML Therapeutics Access and Adoption

Group-level healthcare and policy structures influence how acute myeloid leukemia therapeutics are evaluated, funded, and adopted. The G7 countries generally have mature regulatory systems, advanced oncology infrastructure, robust clinical trial ecosystems, and comparatively broad access to genomic diagnostics, targeted therapies, transplantation, and supportive care, making them important reference points for guideline implementation and real-world evidence generation. The European Union supports harmonized regulatory assessment, cross-border research collaboration, rare disease and cancer research networks, and structured health technology assessment processes, although national reimbursement decisions still shape patient access. BRICS countries are increasingly important in AML care due to large patient populations, expanding hematology capacity, domestic clinical research activity, and rising investment in precision oncology, while access remains uneven across urban and rural settings. ASEAN countries are improving oncology service delivery through expanding tertiary hospitals, regional referral models, and growing laboratory capacity, but affordability and specialist availability continue to influence therapeutic uptake. GCC health systems are investing in advanced cancer centers, molecular testing, international-standard treatment pathways, and transplant capability, supported by national health transformation programs and centralized specialty care models. NATO member countries overlap substantially with high-income markets in North America and Europe, where defense-linked research capabilities, biomedical innovation ecosystems, emergency preparedness frameworks, and coordinated health security planning can indirectly support advanced diagnostics, data infrastructure, and resilient medicine supply chains relevant to complex hematologic cancer care.

Key Country Insights in Acute Myeloid Leukemia Therapeutics

Country-level differences define practical access to acute myeloid leukemia therapeutics. The United States has broad availability of molecular testing, targeted AML medicines, academic leukemia centers, and biomarker-driven trials, though insurance design and treatment affordability remain important access factors. Canada provides guideline-based AML care through provincial systems, with strong transplant expertise and genomic testing adoption shaped by regional funding policies. Mexico and Brazil are advancing hematology oncology capacity through public and private cancer networks, but access to specialized diagnostics, newer targeted therapies, and transplant services varies by geography and payer setting. In the United Kingdom, centralized hematology expertise, national treatment protocols, and structured technology appraisal processes support evidence-based adoption, while Germany and France maintain strong leukemia research networks, transplant infrastructure, molecular diagnostics capabilities, and specialist hematology centers. Italy and Spain deliver advanced AML care through established hematology networks, with regional reimbursement and hospital procurement influencing access timing. Russia has specialized hematology institutions and transplant programs, though geographic access, referral pathways, and medicine availability can vary. China is expanding AML research, genomic testing, and hospital-based oncology capacity at scale, while India is improving access through major cancer centers, increasing transplant activity, and broader diagnostic modernization despite affordability challenges. Japan has a highly developed hematology care environment with strong clinical research, aging-population-driven demand, and regulatory adoption of targeted therapies. Australia provides advanced AML management through national specialist networks and clinical trial participation, and South Korea has sophisticated tertiary hospitals, molecular diagnostics, transplant capabilities, and active hematologic malignancy research supporting modern AML treatment pathways.

Actionable Recommendations for AML Therapeutics Industry Leaders

Industry leaders in acute myeloid leukemia therapeutics should prioritize evidence-based precision medicine strategies that align therapy development, diagnostic access, and real-world clinical needs. First, comprehensive biomarker testing should be embedded early in the patient pathway, including rapid molecular profiling at diagnosis and relapse to support timely treatment selection. Second, development programs should focus on rational combinations that address resistance mechanisms, improve remission durability, and maintain manageable toxicity for older or medically vulnerable patients. Third, stakeholders should invest in measurable residual disease standardization, as MRD-informed decision-making is increasingly central to relapse risk assessment, transplant planning, and post-remission strategies. Fourth, clinical trial designs should broaden inclusion criteria where scientifically appropriate, improve enrollment of older adults and underrepresented populations, and incorporate decentralized or hybrid approaches to reduce participation barriers. Fifth, access strategies should be built on clinical value, diagnostic readiness, and health system affordability, particularly in regions where molecular testing and transplantation capacity remain uneven. Finally, leaders should strengthen pharmacovigilance, supportive care protocols, education for hematology teams, and data partnerships that generate real-world evidence on safety, sequencing, quality of life, adherence, resistance, and long-term outcomes.

Research Methodology for Acute Myeloid Leukemia Therapeutics Analysis

This executive summary is developed using a structured secondary research methodology focused on verified, data-backed evidence from authoritative clinical, regulatory, scientific, and public health sources. The research approach includes review of hematology treatment guidelines, regulatory approval documentation, peer-reviewed oncology journals, clinical trial registries, cancer agency publications, transplant and hematology society materials, and publicly available health system resources. Evidence is assessed for relevance to acute myeloid leukemia therapeutics, including treatment modalities, molecular biomarkers, patient segmentation, regional access patterns, clinical development trends, and emerging technologies such as artificial intelligence. Information is cross-validated across multiple credible sources to reduce bias and ensure consistency with current clinical understanding. The methodology emphasizes qualitative analysis of therapeutic innovation, care delivery dynamics, diagnostic adoption, and policy factors without relying on market sizing, market share estimation, or forecasting. Regional, group, and country insights are synthesized from observable healthcare infrastructure, regulatory frameworks, cancer care capacity, clinical guideline implementation, transplant availability, and documented adoption of precision oncology practices. The analysis is designed to support strategic decision-making for stakeholders involved in AML drug development, diagnostics, clinical research, access planning, and healthcare delivery.

Conclusion: The Future Direction of Acute Myeloid Leukemia Therapeutics

Acute myeloid leukemia therapeutics are entering a more individualized era defined by molecular diagnostics, targeted therapies, combination regimens, measurable residual disease assessment, and expanding clinical research into immune and cellular approaches. The treatment paradigm is moving away from uniform chemotherapy-based care toward adaptive strategies that reflect disease biology, patient fitness, relapse risk, and therapeutic tolerability. Artificial intelligence has the potential to accelerate this transition by improving target discovery, patient-trial matching, risk prediction, and diagnostic interpretation, provided that tools are clinically validated and integrated responsibly. Regional and country-level access remains uneven, with advanced health systems adopting precision AML care more rapidly while resource-constrained settings continue to face barriers in diagnostics, transplantation, supportive care, and affordability. For stakeholders, the central opportunity lies in connecting innovation with practical implementation: faster testing, better treatment sequencing, inclusive trials, robust real-world evidence, and sustainable access models. As AML remains an aggressive and clinically complex disease, progress will depend on coordinated action across therapeutics, diagnostics, digital infrastructure, clinical expertise, and patient-centered care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Acute Myeloid Leukemia Therapeutics Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
    • 7.2.1. Induction Chemotherapy
    • 7.2.2. Consolidation Chemotherapy
  • 7.3. Targeted Therapy
  • 7.4. Immunotherapy
  • 7.5. Stem Cell Transplantation Therapy
  • 7.6. Epigenetic Therapy
  • 7.7. Supportive Care Therapy

8. Acute Myeloid Leukemia Therapeutics Market, by Disease Type

  • 8.1. Introduction
  • 8.2. De Novo AML
  • 8.3. Secondary AML
  • 8.4. Refractory AML
  • 8.5. Acute Promyelocytic Leukemia (APL)
  • 8.6. Tyrosine Kinase Inhibitors

9. Acute Myeloid Leukemia Therapeutics Market, by Molecular Mutation Type

  • 9.1. Introduction
  • 9.2. FLT3-Mutated AML
  • 9.3. IDH-Mutated AML
  • 9.4. NPM1-Mutated AML
  • 9.5. TP53-Mutated AML
  • 9.6. RUNX1-Mutated AML

10. Acute Myeloid Leukemia Therapeutics Market, by Drug Class

  • 10.1. Introduction
  • 10.2. Cytotoxic Agents
  • 10.3. Hypomethylating Agents
  • 10.4. Tyrosine Kinase Inhibitors
  • 10.5. BCL-2 Inhibitors
  • 10.6. Monoclonal Antibodies

11. Acute Myeloid Leukemia Therapeutics Market, by Route of Administration

  • 11.1. Introduction
  • 11.2. Oral
  • 11.3. Parenteral
  • 11.4. Intrathecal

12. Acute Myeloid Leukemia Therapeutics Market, by End User

  • 12.1. Introduction
  • 12.2. Hospitals
  • 12.3. Specialty Cancer Clinics
  • 12.4. Ambulatory Surgical Centers
  • 12.5. Research Institutes
  • 12.6. Homecare Settings

13. Acute Myeloid Leukemia Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Acute Myeloid Leukemia Therapeutics Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Acute Myeloid Leukemia Therapeutics Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Actinium Pharmaceuticals, Inc.
  • 17.3. Agios Pharmaceuticals, Inc.
  • 17.4. Amgen Inc.
  • 17.5. Astellas Pharma Inc.
  • 17.6. Astex Pharmaceuticals, Inc. by Otsuka Group
  • 17.7. Celgene Corporation
  • 17.8. CTI BioPharma Corp.
  • 17.9. Cyclacel Pharmaceuticals, Inc.
  • 17.10. Daiichi Sankyo Company, Limited
  • 17.11. Eisai Co., Ltd.
  • 17.12. F. Hoffmann-La Roche AG
  • 17.13. GlaxoSmithKline plc
  • 17.14. Jazz Pharmaceuticals PLC
  • 17.15. Johnson & Johnson Services, Inc.
  • 17.16. MEI Pharma, Inc.
  • 17.17. Merck KGaA
  • 17.18. Merus N.V.
  • 17.19. Novartis AG
  • 17.20. Otsuka Pharmaceutical Co., Ltd.
  • 17.21. Partner Therapeutics, Inc.
  • 17.22. Pfizer Inc.
  • 17.23. Rigel Pharmaceuticals, Inc.
  • 17.24. Sanofi S.A.
  • 17.25. Servier Pharmaceuticals LLC
  • 17.26. Sun Pharmaceutical Industries Ltd.
  • 17.27. Takeda Pharmaceutical Company Limited
  • 17.28. Teva Pharmaceutical Industries Ltd.
  • 17.29. The Bristol Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INDUCTION CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INDUCTION CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INDUCTION CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONSOLIDATION CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONSOLIDATION CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONSOLIDATION CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL TRANSPLANTATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL TRANSPLANTATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL TRANSPLANTATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EPIGENETIC THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EPIGENETIC THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EPIGENETIC THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SUPPORTIVE CARE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SUPPORTIVE CARE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SUPPORTIVE CARE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DE NOVO AML MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DE NOVO AML MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DE NOVO AML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SECONDARY AML MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SECONDARY AML MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SECONDARY AML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL REFRACTORY AML MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL REFRACTORY AML MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL REFRACTORY AML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE PROMYELOCYTIC LEUKEMIA (APL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE PROMYELOCYTIC LEUKEMIA (APL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE PROMYELOCYTIC LEUKEMIA (APL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FLT3-MUTATED AML MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FLT3-MUTATED AML MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FLT3-MUTATED AML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IDH-MUTATED AML MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IDH-MUTATED AML MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IDH-MUTATED AML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NPM1-MUTATED AML MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NPM1-MUTATED AML MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NPM1-MUTATED AML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TP53-MUTATED AML MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TP53-MUTATED AML MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TP53-MUTATED AML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RUNX1-MUTATED AML MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RUNX1-MUTATED AML MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RUNX1-MUTATED AML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HYPOMETHYLATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HYPOMETHYLATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HYPOMETHYLATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BCL-2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BCL-2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BCL-2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SPECIALTY CANCER CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SPECIALTY CANCER CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SPECIALTY CANCER CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 303. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULAR MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 319. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTIC